HC Wainwright Forecasts Assertio’s Q4 Earnings (NASDAQ:ASRT)

Assertio Holdings, Inc. (NASDAQ:ASRT) – Analysts at HC Wainwright raised their Q4 2026 earnings estimates for Assertio in a research report issued on Monday, January 5th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $1.22 for the quarter, up from their prior forecast of $1.20. HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Assertio’s current full-year earnings is ($0.15) per share.

Other analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a research note on Wednesday, October 8th. Wall Street Zen upgraded Assertio to a “buy” rating in a report on Saturday, November 22nd. Finally, Zacks Research raised Assertio from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.63.

Assertio Stock Down 1.0%

ASRT stock opened at $9.53 on Tuesday. The stock has a market capitalization of $61.18 million, a price-to-earnings ratio of -2.05 and a beta of 0.61. The company has a 50-day moving average of $11.04 and a two-hundred day moving average of $11.48. Assertio has a 52-week low of $7.65 and a 52-week high of $15.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.58 and a quick ratio of 1.43.

Assertio (NASDAQ:ASRT) last posted its quarterly earnings data on Monday, November 10th. The company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $2.85. The business had revenue of $49.46 million during the quarter, compared to the consensus estimate of $27.02 million. Assertio had a negative net margin of 21.06% and a negative return on equity of 26.99%.

Institutional Trading of Assertio

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of Assertio during the third quarter valued at approximately $26,000. Belpointe Asset Management LLC bought a new position in Assertio in the first quarter worth $65,000. TSP Capital Management Group LLC boosted its stake in Assertio by 12.2% during the second quarter. TSP Capital Management Group LLC now owns 316,875 shares of the company’s stock worth $203,000 after buying an additional 34,550 shares in the last quarter. Perritt Capital Management Inc increased its holdings in Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock valued at $309,000 after buying an additional 119,281 shares during the period. Finally, GSA Capital Partners LLP increased its holdings in Assertio by 536.0% in the 3rd quarter. GSA Capital Partners LLP now owns 381,584 shares of the company’s stock valued at $336,000 after buying an additional 321,584 shares during the period. Institutional investors own 48.96% of the company’s stock.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.